Nov 30, 2022 09:31 JST

Source: Biogen

Eleven Experts from Leading Medical Institutions and Eight Experts from Eisai Publish Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer's Disease in the New England Journal of Medicine

TOKYO, Nov 30, 2022 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that the results from Eisai's large global Phase 3 confirmatory Clarity AD clinical study of lecanemab (development code: BAN2401), an investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD) with confirmed presence of amyloid pathology in the brain, were published in the New England Journal of Medicine, one of the world's most prestigious peer-reviewed medical journals. For the details of the paper, please refer to: www.nejm.org/doi/full/10.1056/NEJMoa2212948.

The rapid publication of the Clarity AD study results demonstrates Eisai's strong commitment to trust and transparency based on Eisai's human health care mission. Eisai and Biogen remain committed to disclosing data and information on lecanemab. If approved, we will work to bring the drug expeditiously to people living with early AD and their families.

Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.

This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such an investigational agent will successfully gain health authority approval.

For more information, visit www.eisai.com/news/2022/pdf/enews202284pdf.pdf.

Source: Biogen
Sectors: BioTech

Copyright ©2023 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai's Sales Subsidiary Collaborates with Ministry of Public Health (MOPH) in Thailand
November 30 2023 15:25 JST
 
Eisai to Present Latest Data on Perampanel at The 77th American Epilepsy Society (AES) Annual Meeting
November 22 2023 08:28 JST
 
LEQEMBI Wins Best New Drug And Clinical Advance of The Year at The Scrip Awards 2023
November 20 2023 16:05 JST
 
LEQEMBI (lecanemab-Irmb) Named One of Time's Best Inventions of 2023
October 25 2023 19:43 JST
 
Eisai to Present New Data from LEQEMBI (Lecanemab-Irmb) Phase 3 Clarity Ad Study and Other Alzheimer's Disease Pipeline Research at The Clinical Trials on Alzheimer's Disease (CTAD) Conference
October 16 2023 13:07 JST
 
Eisai to Present Research from Oncology Portfolio and Pipeline at ESMO Congress 2023
October 11 2023 12:07 JST
 
Eisai: Notice of Absorption-Type Merger (Simplified Merger/Short-Form Merger) of KAN Research Institute, Inc.
October 04 2023 18:08 JST
 
Eisai Launches New "Innovation" Page on Corporate Website
September 28 2023 16:05 JST
 
Tokio Marine Nichido and Eisai Co-Develop Industry's First "Dementia Care Support Insurance"
September 28 2023 13:49 JST
 
"LEQEMBI Intravenous Infusion" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Japan
September 25 2023 14:17 JST
 
More Press release >>

Latest Press Release


More Latest Release >>